CR20230074A - Agonistas del receptor npy2 solubles - Google Patents

Agonistas del receptor npy2 solubles

Info

Publication number
CR20230074A
CR20230074A CR20230074A CR20230074A CR20230074A CR 20230074 A CR20230074 A CR 20230074A CR 20230074 A CR20230074 A CR 20230074A CR 20230074 A CR20230074 A CR 20230074A CR 20230074 A CR20230074 A CR 20230074A
Authority
CR
Costa Rica
Prior art keywords
soluble
receptor agonists
analogues
npy2 receptor
relates
Prior art date
Application number
CR20230074A
Other languages
English (en)
Inventor
Søren Ljungberg Pedersen
Charlotte Stahl Madsen
Peter Haebel
Albert Brennauer
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20230074A publication Critical patent/CR20230074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a análogos de PYY que tienen alanina en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de semivida. Los análogos de la invención son solubles a alrededor de pH 6 y 7. La invención también se refiere a composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos.<br /> <br />
CR20230074A 2020-08-07 2021-08-05 Agonistas del receptor npy2 solubles CR20230074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20189966 2020-08-07
PCT/EP2021/071873 WO2022029231A1 (en) 2020-08-07 2021-08-05 Soluble npy2 receptor agonists

Publications (1)

Publication Number Publication Date
CR20230074A true CR20230074A (es) 2023-04-19

Family

ID=71995807

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230074A CR20230074A (es) 2020-08-07 2021-08-05 Agonistas del receptor npy2 solubles

Country Status (19)

Country Link
US (1) US20220041678A1 (es)
EP (1) EP4192853A1 (es)
JP (1) JP2023537036A (es)
KR (1) KR20230045088A (es)
CN (1) CN116171282A (es)
AR (1) AR123174A1 (es)
AU (1) AU2021322137A1 (es)
BR (1) BR112022025623A2 (es)
CA (1) CA3185637A1 (es)
CL (1) CL2023000357A1 (es)
CO (1) CO2023000637A2 (es)
CR (1) CR20230074A (es)
DO (1) DOP2023000010A (es)
EC (1) ECSP23003649A (es)
IL (1) IL300239A (es)
MX (1) MX2023001532A (es)
PE (1) PE20231566A1 (es)
TW (1) TW202222335A (es)
WO (1) WO2022029231A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422807A3 (en) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
WO2006066024A2 (en) 2004-12-13 2006-06-22 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
MX2010005345A (es) 2007-11-14 2010-08-31 Amylin Pharmaceuticals Inc Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
AU2008365559B2 (en) 2008-12-15 2016-02-25 Zealand Pharma A/S Glucagon analogues
EP2799447B1 (en) 2008-12-15 2016-11-23 Zealand Pharma A/S Glucagon analogues
CN102292347A (zh) 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
KR20110126591A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
HUE026255T2 (en) 2009-07-13 2016-06-28 Zealand Pharma As Acylated glucagon analogues
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
EP2718314A2 (en) 2011-06-10 2014-04-16 Novo Nordisk A/S Polypeptides
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
IN2014MN02304A (es) 2012-05-03 2015-08-07 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
KR20160003848A (ko) 2013-05-02 2016-01-11 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 치료용 펩티드
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
EP3057984B1 (en) 2013-10-17 2018-07-11 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
RU2689551C1 (ru) 2013-11-14 2019-05-28 Кибайосайнс Аг Миметик кальцитонина для лечения болезней и нарушений
JP6602760B2 (ja) 2013-11-15 2019-11-06 ノヴォ ノルディスク アー／エス 選択的なｐｙｙ化合物及びその使用
WO2016146739A1 (en) 2015-03-18 2016-09-22 Zealand Pharma A/S Amylin analogues
ES2763329T3 (es) 2015-04-16 2020-05-28 Zealand Pharma As Análogo de glucagón acilado
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
MA43205A (fr) 2015-06-12 2018-09-19 Novo Nordisk As Composés pyy sélectifs et leurs utilisations
CR20180380A (es) 2015-12-31 2018-12-07 Hanmi Pharm Ind Co Ltd Agosnista triple de receptores de glucagón/glp-1/gip
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
TW202208410A (zh) * 2018-11-01 2022-03-01 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
AU2020384729A1 (en) * 2019-11-11 2022-04-14 Boehringer Ingelheim International Gmbh NPY2 receptor agonists

Also Published As

Publication number Publication date
CN116171282A (zh) 2023-05-26
WO2022029231A1 (en) 2022-02-10
KR20230045088A (ko) 2023-04-04
DOP2023000010A (es) 2023-02-15
EP4192853A1 (en) 2023-06-14
JP2023537036A (ja) 2023-08-30
AU2021322137A1 (en) 2023-01-19
CO2023000637A2 (es) 2023-01-26
ECSP23003649A (es) 2023-03-31
BR112022025623A2 (pt) 2023-03-07
AR123174A1 (es) 2022-11-02
TW202222335A (zh) 2022-06-16
PE20231566A1 (es) 2023-10-04
CA3185637A1 (en) 2022-02-10
MX2023001532A (es) 2023-03-08
US20220041678A1 (en) 2022-02-10
CL2023000357A1 (es) 2023-09-29
IL300239A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
EA202192588A1 (ru) Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения
MX2023001532A (es) Agonistas del receptor npy2 solubles.
CR20220206A (es) Agonistas del receptor npy2
PH12015501579B1 (en) Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration
PH12018502465A1 (en) Mic-1 compounds and use thereof
PH12019550241A1 (en) Mic-1 compounds and uses thereof
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
WO2011054001A3 (en) Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
MX2021004930A (es) Analogos de proteina tirosina-tirosina y metodos de uso de esta.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
MX2022001719A (es) Formulaciones de conjugados de benzazepina y usos de las mismas.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
PH12020551659A1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
MX2022008748A (es) Administración oral de péptidos.
MX2022013550A (es) Composiciones y metodos para suministrar agentes farmaceuticamente activos.
MX2019010360A (es) Peptido modificado de helicobacter pylori para inducir inmunogenicidad contra infecciones ocasionadas por h. pylori.
RS20170169A1 (sr) Poboljšana rekonstituisana kompozicija sufraktanta koja sadrži analoge sufraktanta proteina b (sp-b) i surfaktanta proteina c (sp-c)
UA104870C2 (uk) Стабільна пероральна тверда композиція поліпептидного агоніста gc-c рецептора лінаклотиду та спосіб її одержання
AR063251A1 (es) Compuesto peptidico pegilado composicion farmaceutica que lo comprende y su uso para fabricacion de un medicamento